Cargando…
A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin
Coronary artery disease (CAD) is one of the most common subtypes of cardiovascular disease. The progression of CAD initiates from the plaque of atherosclerosis and coronary artery stenosis, and eventually turns into acute myocardial infarction (AMI) or stable CAD. Alpha-1-antichymotrypsin (AACT) has...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222053/ https://www.ncbi.nlm.nih.gov/pubmed/35741224 http://dx.doi.org/10.3390/diagnostics12061415 |
_version_ | 1784732778456154112 |
---|---|
author | Chang, Chen-Chi Tsai, I-Jung Shen, Wen-Chi Chen, Hung-Yi Hsu, Po-Wen Lin, Ching-Yu |
author_facet | Chang, Chen-Chi Tsai, I-Jung Shen, Wen-Chi Chen, Hung-Yi Hsu, Po-Wen Lin, Ching-Yu |
author_sort | Chang, Chen-Chi |
collection | PubMed |
description | Coronary artery disease (CAD) is one of the most common subtypes of cardiovascular disease. The progression of CAD initiates from the plaque of atherosclerosis and coronary artery stenosis, and eventually turns into acute myocardial infarction (AMI) or stable CAD. Alpha-1-antichymotrypsin (AACT) has been highly associated with cardiac events. In this study, we proposed incorporating clinical data on AACT levels to establish a model for estimating the severity of CAD. Thirty-six healthy controls (HCs) and 162 CAD patients with stenosis rates of <30%, 30–70%, and >70% were included in this study. Plasma concentration of AACT was determined by enzyme-linked immunosorbent assay (ELISA). The receiver operating characteristic (ROC) curve analysis and associations were conducted. Further, five machine learning models, including decision tree, random forest, support vector machine, XGBoost, and lightGBM were implemented. The lightGBM model obtained a sensitivity of 81.4%, a specificity of 67.3%, and an area under the curve (AUC) of 0.822 for identifying CAD patients with a stenosis rate of <30% versus >30%. In this study, we provided a demonstration of a monitoring model with clinical data and AACT. |
format | Online Article Text |
id | pubmed-9222053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92220532022-06-24 A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin Chang, Chen-Chi Tsai, I-Jung Shen, Wen-Chi Chen, Hung-Yi Hsu, Po-Wen Lin, Ching-Yu Diagnostics (Basel) Article Coronary artery disease (CAD) is one of the most common subtypes of cardiovascular disease. The progression of CAD initiates from the plaque of atherosclerosis and coronary artery stenosis, and eventually turns into acute myocardial infarction (AMI) or stable CAD. Alpha-1-antichymotrypsin (AACT) has been highly associated with cardiac events. In this study, we proposed incorporating clinical data on AACT levels to establish a model for estimating the severity of CAD. Thirty-six healthy controls (HCs) and 162 CAD patients with stenosis rates of <30%, 30–70%, and >70% were included in this study. Plasma concentration of AACT was determined by enzyme-linked immunosorbent assay (ELISA). The receiver operating characteristic (ROC) curve analysis and associations were conducted. Further, five machine learning models, including decision tree, random forest, support vector machine, XGBoost, and lightGBM were implemented. The lightGBM model obtained a sensitivity of 81.4%, a specificity of 67.3%, and an area under the curve (AUC) of 0.822 for identifying CAD patients with a stenosis rate of <30% versus >30%. In this study, we provided a demonstration of a monitoring model with clinical data and AACT. MDPI 2022-06-08 /pmc/articles/PMC9222053/ /pubmed/35741224 http://dx.doi.org/10.3390/diagnostics12061415 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chang, Chen-Chi Tsai, I-Jung Shen, Wen-Chi Chen, Hung-Yi Hsu, Po-Wen Lin, Ching-Yu A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title | A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title_full | A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title_fullStr | A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title_full_unstemmed | A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title_short | A Coronary Artery Disease Monitoring Model Built from Clinical Data and Alpha-1-Antichymotrypsin |
title_sort | coronary artery disease monitoring model built from clinical data and alpha-1-antichymotrypsin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222053/ https://www.ncbi.nlm.nih.gov/pubmed/35741224 http://dx.doi.org/10.3390/diagnostics12061415 |
work_keys_str_mv | AT changchenchi acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT tsaiijung acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT shenwenchi acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT chenhungyi acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT hsupowen acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT linchingyu acoronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT changchenchi coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT tsaiijung coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT shenwenchi coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT chenhungyi coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT hsupowen coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin AT linchingyu coronaryarterydiseasemonitoringmodelbuiltfromclinicaldataandalpha1antichymotrypsin |